Supernus Pharmaceuticals | SUPN - Debt


Supernus Pharmaceuticals reported $40.98M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Abbott USD 13.86B 919M Dec/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 6.11M 251K Dec/2025
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025